Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Imilecleucel-T - Acer Therapeutics

Drug Profile

Imilecleucel-T - Acer Therapeutics

Alternative Names: Autologous T cell vaccine - Acer Therapeutics; Tcelna; Tovaxin®

Latest Information Update: 08 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Opexa Therapeutics
  • Developer Acer Therapeutics
  • Class Immunotherapies; T lymphocyte cell therapies; Vaccines
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Multiple sclerosis

Most Recent Events

  • 08 Aug 2019 Imilecleucel-T is still in phase II trial for Multiple sclerosis (First-line therapy) in USA, Canada (SC) (Opexa Therapeutics website, August 2017)
  • 19 Sep 2017 Acer Therapeutics merged with Opexa Therapeutics and the combined company has been named as Acer Therapeutics
  • 01 Oct 2016 Opexa Therapeutics completes the phase IIb Abili-T trial for secondary progressive Multiple sclerosis in USA and Canada (NCT01684761)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top